AngioDynamics launches long-term study of NanoKnife for prostate cancer

AngioDynamics has teamed up with the University College London Hospital (UCLH) in the UK to launch a prospective registry study evaluating the long-term effects of the NanoKnife system for treating unifocal intermediate-risk prostate cancer.